All In Biotech

Drug Trial Radar · NCT06308874

Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females

A Double-Blind, Placebo Controlled, Single Dosing, Dose-Escalation Phase 1 Clinical Trial to Investigate the Safety, Tolerability, PK/PD of J2H-1702 After Oral Administration in Healthy Female Subjects

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jan 2, 2023

Primary completion

Feb 17, 2023

Study completion Feb 17, 2023

Sponsor

Lead sponsor
J2H BiotechIndustry
Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 19 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

\- Objectives: Primary objective\_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects. Secondary objective\_To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics after single oral administration of the IP, J2H-1702 in healthy female subjects.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

  • Amg dose administration groupDrug

    Orally, Amg tablet single administration

  • Amg dose administration group- PlaceboDrug

    Orally, Placebo Amg tablet single administration

  • Bmg dose administration groupDrug

    Orally, Bmg tablet single administration

  • Bmg dose administration group- PlaceboDrug

    Orally, Placebo Bmg tablet single administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours (After IP administration)
  2. EmaxTime frame: -1day 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours, 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours (After IP administration)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • J2H Biotech

    Suwon, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.